Wyss Centre initiates collaboration to improve brain tumour treatment
The Wyss Centre has announced a collaborative project to improve understanding of the brain cancer glioblastoma and develop new personalised therapies.
List view / Grid view
The Wyss Centre has announced a collaborative project to improve understanding of the brain cancer glioblastoma and develop new personalised therapies.
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
Interleukin 13 receptor alpha 2 was found in increased rates in cancer cells that metastasised to the brain and lungs, a new study has shown.
A nanotherapeutic delivery system displayed high efficacy against metastatic tumours in mice, potentially improving chemotherapy treatments.
Researchers testing 2-deoxy-D-glucose in mouse models of ovarian cancer report that the compound significantly improves the effectiveness of the chemotherapy drug, carboplatin.
Researchers demonstrated NSPP completely prevented cognitive decline in mice treated with radiation for patient-derived glioblastomas.
Researchers combined cisplatin, an enhancer and a photodynamic therapy (PDT) drug into a single conjugate that had 10 times the efficacy in treating treatment resistant cancer cells.
Scientists have identified that the TEX264 protein and associated enzymes protect the genome from damage, which could lead to new anti-ageing and neurodegeneration therapies.
A team of researchers in Singapore has studied the activity of a receptor protein to identify whether it’s a key player in the development of neuropathy for patients undergoing chemotherapy.
Research demonstrated a complex of palladium and thiosemicarbazone is a more selective and powerful chemotherapeutic than the current standard of care cisplatin.
Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies.
Research indicates that activation of the RICTOR/mTORC2 pathway advances cancer metastasis and suggests that inhibiting this signalling may make chemotherapy more effective against colon cancer.
VTP50469, a new targeted therapy for MLL-rearranged leukaemia, shows greater efficacy and fewer side-effects in mice, according to new research.
A pioneering team of scientists from Rice University has discovered that a particular combination of chemotherapeutics, including mitocans that target mitochondria, form a powerful treatment for acute myeloid leukaemia patients.